In critical trauma situations, stopping bleeding quickly is often the difference between life and death. This is especially true during the “Golden Hour”—the first 60 minutes after a traumatic or battlefield injury—when rapid medical intervention can drastically improve survival outcomes. Alarming research shows that nearly 50% of military fatalities are caused by uncontrolled bleeding, and approximately 80% of trauma-related deaths occur within the first hour.

At Axio Biosolutions, saving lives during this vital window is the core mission. Their flagship product, Axiostat, is an advanced bleeding control solution developed to meet the demands of high-pressure trauma care. Made entirely from chitosan, a biopolymer known for its haemostatic properties, Axiostat is a clinically validated dressing available in sponge, Z-fold, and rolled gauze formats, offering both versatility and ease of use across a wide range of wound types.

Haemostatic dressings have long played a critical role in emergency care, particularly in military, prehospital, and surgical settings. However, with an increasing number of patients on anticoagulant therapy, conventional gauze and clot-promoting bandages often fall short. That’s where Axiostat stands apart. Its innovative molecular structure and bioadhesive properties allow it to control heavy bleeding effectively, even in patients with impaired clotting ability, making it a reliable, next-generation solution for today’s evolving medical challenges.

A New Frontier in Hemostatic Dressing Design & Development Background

Historically, haemostatic dressings have primarily relied on standard cotton gauze made from cellulose materials. However, these conventional gauze dressings do not possess inherent haemostatic properties and are ineffective in rapidly controlling severe bleeding.

Recent studies have shown that Axiostat dressings are effective in managing bleeding during emergencies and trauma situations, particularly in pre-hospital settings[1], [2] Over time, other haemostatic dressings, such as kaolin- or chitosan-coated gauze and oxidized regenerated cellulose (ORC) gauze, have been developed to improve bleeding control. However, these dressings have limitations—they may be less effective in stopping severe bleeding quickly and pose a risk of embolism due to the potential leaching of coated or impregnated particles during massive bleeding events.

In contrast, Axiostat is made from 100% chitosan and carries no risk of particle embolism or leaching. A recent comparative study has also demonstrated that Axiostat provides faster haemostasis and greater reduction in blood loss than kaolin-based gauze[3]

How Axiostat Stops Bleeding 

Axiostat utilizes Protonated Bioadhesive Technology (PBT) to achieve the hemostasis action. It includes 4 major aspects: including charge-based interaction with blood components, platelet activation via TLR receptors, clotting cascade activation via factor X, and robust fibrin seal formation at the bleeding site. Axiostat acts by adhering strongly to blood and activating platelets through the TLR (Toll-like receptor) pathway, making it effective even in patients with coagulopathy disorders[4]. 

Real-world Application of Axiostat 

Military Setting and Battlefield  Use: In India, Axiostat has been proudly deployed across more than 300 battalions of the frontline Indian Armed Forces. It has been extensively used to manage life-threatening bleeding from gunshot wounds and IED blast injuries. Apart from battlefield or military settings, Axiostat is also useful for soldiers in challenging natural disaster scenarios, such as during any calamities like earthquakes, fires, Landslides, etc. Axiostat is proudly endorsed by several frontline battalions of the Indian Armed Forces, and it has earned widespread testimonials and success stories for saving lives in battlefield trauma, gunshot wounds, and blast injuries. Explore real-world case studies and testimonials at: https://axiostatmilitary.com/success-stories

Surgical and Interventional Use: With increasing numbers of patients undergoing surgeries and vascular procedures, including radial or femoral catheterizations while on blood thinners, Axiostat offers a safer, faster alternative to traditional blood clot bandages and compression devices.

Conclusion 

In the high-stakes world of trauma care, where every second can determine a patient’s fate, Axiostat is redefining what’s possible in bleeding control. Backed by science, trusted by military and medical professionals, and proven in real-world emergencies—from battlefield injuries to surgical bleeding—Axiostat stands as a next-generation haemostatic solution. Its unique 100% chitosan composition, advanced Protonated Bioadhesive Technology (PBT), and particle-free design make it both safe and highly effective, even in the most compromised clinical scenarios. As trauma management continues to evolve, Axiostat is not just keeping pace—it’s setting a new standard for rapid, reliable, and life-saving haemostasis when it matters most.

Reference 

[1] P. Ketan, P. Anjali, P. Rignesh, P. Bhavika, P. Priyank, and P. Dev, “Assessing the Efficacy of Haemostatic Dressing Axiostat® In Trauma Care at a Tertiary Care Hospital in India: A Comparison with Conventional Cotton Gauze,” Indian Journal of Emergency Medicine, vol. 2, no. 2, pp. 93–99, 2016, doi: 10.21088/ijem.2395.311x.2216.1.

[2] M. Kabeer, P. P. Venugopalan, and V. C. Subhash, “Pre-hospital Hemorrhagic Control Effectiveness of Axiostat® Dressing Versus Conventional Method in Acute Hemorrhage Due to Trauma,” Cureus, vol. 11, no. 8, 2019.

[3] A. Kumar, Animesh Agrawal, Kala Kumar Bharani, and Leo Mavely, “Evaluation of Hemostatic Effectiveness in a Standard Swine Hemorrhage Model of Severe Bleeding: A Comparative Study of Chitosan Gauze and Kaolin Gauze,” International Journal of Health Technology and Innovation, vol. 3, no. 02, pp. 38–47, Aug. 2024, doi: 10.60142/ijhti.v3i02.07.

[4] V. K. Lee et al., “An architecturally rational hemostat for rapid stopping of massive bleeding on anticoagulation therapy,” Proc Natl Acad Sci U S A, vol. 121, no. 5, 2024, doi: 10.1073/pnas.2316170121.